Automated antimicrobial susceptibility testing products are of two types, consumables and instruments. Consumables used in automated antimicrobial susceptibility testing includes culture & growth media, ready-to-use reagents, complete reagent kits, susceptibility disks, susceptibility plates, and susceptibility cards, among others. Key players offer reagent kits and disposables, which are designed for use with their automated AST instruments, which optimizes workflow and overall laboratory efficiency. Automated microbial identification and antimicrobial susceptibility testing (AST) instruments offer rapid, accurate, and efficient susceptibility testing, thereby enhancing workflow, reducing hands-on time, and enabling rapid reporting. Automated laboratory AST instruments are equipped with Laboratory Information System (LIS) compatible software to enable better compatibility.
For Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2622
Increasing prevalence of antibiotic resistance worldwide is expected to boost the automated antimicrobial susceptibility testing market growth. According to the World Health Organization’s Global Antimicrobial Surveillance System (GLASS) report of January 2018, antibiotic resistance is found among 500,000 people with suspected bacterial infections across 22 countries. The most commonly reported resistant bacteria were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae, followed by Salmonella sp.
However, the major restraining factor affecting growth of the automated antimicrobial susceptibility testing market is the product recalls of instruments for failures or for various other reasons. For instance, in 2016, bioMérieux S.A.’s VITEK 2 Gram Positive Susceptibility Test Cards were recalled by the Food and Drug Administration (FDA), as the product could lead to false susceptible results of Staphylococcus spp., Enterococcus spp., and S. agalactiae. This product was terminated in May 2017.
Key players are engaged in launching susceptibility testing systems in the market, in order to expand its product portfolio. For instance, in March 2016, Thermo Fisher Scientific launched antimicrobial susceptibility testing for Tedizolid, enabling microbiology laboratories to perform Tedizolid susceptibility testing of fastidious and non-fastidious Gram positive organisms, which cause acute bacterial skin and skin structure infections (ABSSSIs) in adults. Increasing launch of such AST testing could result in increasing adoption of susceptibility plates during the forecast period.
Moreover, in 2017, bioMérieux launched ETEST Ceftolozane/Tazobactam and ETEST Ceftazidime/Avibactam, which determines the minimum inhibitory concentration (MIC) values necessary to effectively treat infections caused by multidrug resistant organisms.
Browse 38 Market Data Tables and 25 Figures spread through 200 Pages and in-depth TOC on “Automated Antimicrobial Susceptibility Testing Market, By Product Type (Consumables and Instruments), By Detection Method (Turbidimetric and Colorimetric), By Application (Antibacterial (Tuberculosis and Sepsis), Antifungal, Anti-parasitic, and Anti-viral), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals, and Pathology/Diagnostic Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”
For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/market-insight/automated-antimicrobial-susceptibility-testing-market-2622
Rising funding for research of antibiotic resistant microbes is expected to boost the automated antimicrobial susceptibility testing market revenue over the forecast period. For instance, in November 2017, Symcel AB, a company engaged in cell-based assay tool for real-time cell metabolism measurements, secured US$ 4.23 million Horizon 2020 funding to support the company’s evaluation of improved combination testing of antibiotics against extensively drug-resistant bacteria in sepsis patients.